Paper40430482
Norfloxacin Derivative with Carbazole at C-7 FQB-1 Induces Cytotoxic, Antiproliferative, and Antitumor Effects in an Experimental Lung Carcinoma Model.
Bocanegra-Zapata A and 9 others. Pharmaceuticals (Basel), 2025. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Norfloxacin Derivative with Carbazole at C-7 FQB-1 Induces Cytotoxic, Antiproliferative, and Antitumor Effects in an Experimental Lung Carcinoma Model. Papers, record 40430482. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40430482
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Norfloxacin Derivative with Carbazole at C-7 FQB-1 Induces Cytotoxic, Antiproliferative, and Antitumor Effects in an Experimental Lung Carcinoma Model.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References31
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 35633535 | Antiproliferative Activities of Lipophililic Fluoroquinolones- Based Scaffold Against a Panel of Solid and Liquid Cancer Cell Lines. | Asian Pac J Cancer Prev | 2022 | https://conductscience.org/library/papers/35633535 | PubMed |
| 2 | 27976571 | [Fluoroquinolones: Non-antibacterial properties]. | Rev Esp Quimioter | 2017 | https://conductscience.org/library/papers/27976571 | PubMed |
| 3 | 38756586 | Betaglycan sustains HGF/Met signaling in lung cancer and endothelial cells promoting cell migration and tumor growth. | Heliyon | 2024 | https://conductscience.org/library/papers/38756586 | PubMed |
| 4 | 28977631 | Producing irreversible topoisomerase II-mediated DNA breaks by site-specific Pt(II)-methionine coordination chemistry. | Nucleic Acids Res | 2017 | https://conductscience.org/library/papers/28977631 | PubMed |
| 5 | 28667488 | Molecular docking studies on thirteen fluoroquinolines with human topoisomerase II a and b. | In Silico Pharmacol | 2016 | https://conductscience.org/library/papers/28667488 | PubMed |
| 6 | 34846393 | The modern role of boron as a 'magic element' in biomedical science: chemistry perspective. | Chem Commun (Camb) | 2021 | https://conductscience.org/library/papers/34846393 | PubMed |
| 7 | 29546541 | The Physiological Role of Boron on Health. | Biol Trace Elem Res | 2018 | https://conductscience.org/library/papers/29546541 | PubMed |
| 8 | 31803393 | Quinolone antibiotics. | Medchemcomm | 2019 | https://conductscience.org/library/papers/31803393 | PubMed |
| 9 | 39228758 | Levofloxacin reposition-based design: synthesis, biological evaluation of new levofloxacin derivatives targeting topoisomerase II beta polymerase as promising anticancer agents, molecular docking, and physicochemical characterization. | RSC Adv | 2024 | https://conductscience.org/library/papers/39228758 | PubMed |
| 10 | 23495937 | New mechanistic and functional insights into DNA topoisomerases. | Annu Rev Biochem | 2013 | https://conductscience.org/library/papers/23495937 | PubMed |
| 11 | 31487867 | Molecular Docking: Shifting Paradigms in Drug Discovery. | Int J Mol Sci | 2019 | https://conductscience.org/library/papers/31487867 | PubMed |
| 12 | 28442170 | Platinum, palladium, gold and ruthenium complexes as anticancer agents: Current clinical uses, cytotoxicity studies and future perspectives. | Eur J Med Chem | 2017 | https://conductscience.org/library/papers/28442170 | PubMed |
| 13 | 28523239 | Cisplatin, Etoposide, and Irinotecan for Relapsed Small-Cell Lung Cancer. | Transl Cancer Res | 2016 | https://conductscience.org/library/papers/28523239 | PubMed |
| 14 | 36914702 | Design and synthesis of novel cytotoxic fluoroquinolone analogs through topoisomerase inhibition, cell cycle arrest, and apoptosis. | Sci Rep | 2023 | https://conductscience.org/library/papers/36914702 | PubMed |
| 15 | 17348830 | Antitumor carbazoles. | Anticancer Agents Med Chem | 2007 | https://conductscience.org/library/papers/17348830 | PubMed |
| 16 | 38613572 | Biological evaluation of levofloxacin and its thionated derivatives: antioxidant activity, aldehyde dehydrogenase enzyme inhibition, and cytotoxicity on A549 cell line. | Naunyn Schmiedebergs Arch Pharmacol | 2024 | https://conductscience.org/library/papers/38613572 | PubMed |
| 17 | 34463935 | Lipophilic Conjugates of Drugs: A Tool to Improve Drug Pharmacokinetic and Therapeutic Profiles. | Pharm Res | 2021 | https://conductscience.org/library/papers/34463935 | PubMed |
| 18 | 30357526 | Oral etoposide in heavily pre-treated metastatic breast cancer: results from the ESME cohort and comparison with other chemotherapy regimens. | Breast Cancer Res Treat | 2019 | https://conductscience.org/library/papers/30357526 | PubMed |
| 19 | 32516852 | Radiotherapy treatment for lung cancer: Current status and future directions. | Respirology | 2020 | https://conductscience.org/library/papers/32516852 | PubMed |
| 20 | 26529666 | Trypan Blue Exclusion Test of Cell Viability. | Curr Protoc Immunol | 2015 | https://conductscience.org/library/papers/26529666 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40430482
GET https://conductscience.org/api/papers/v1/40430482/references?page=2